Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 18/20 | 0.78 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.68 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | DHODH | Q02127 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5008485 | 0.92 | ADORA1 (0.79) | ADORA1ADORA3ADORA2BADORA2AKDM4E | |
| SCHEMBL5007775 | 0.90 | ADORA1 (0.79) | ADORA1ADORA3ADORA2BADORA2AKDM4E | |
| SCHEMBL5087428 | 0.90 | ADORA1 (0.73) | ADORA1ADORA3ADORA2BADORA2AKDM4E | |
| SCHEMBL5007774 | 0.89 | ADORA1 (0.81) | ADORA1ADORA3ADORA2BADORA2AKDM4E | |
| SCHEMBL5008333 | 0.89 | ADORA1 (0.79) | ADORA1ADORA3ADORA2BADORA2AKDM4E | |
| SCHEMBL5012091 | 0.88 | ADORA1 (0.79) | ADORA1ADORA3ADORA2BADORA2AKDM4E | |
| SCHEMBL3304018 | 0.88 | ADORA1 (0.77) | ADORA1ADORA3ADORA2BADORA2A | |
| SCHEMBL5010548 | 0.88 | ADORA1 (0.94) | ADORA1ADORA3ADORA2BADORA2AKDM4E | |
| SCHEMBL5005394 | 0.88 | ADORA1 (0.90) | ADORA1ADORA3ADORA2BADORA2A | |
| SCHEMBL5005230 | 0.88 | ADORA1 (0.74) | ADORA1ADORA3ADORA2BADORA2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-03-13 | — | — | US | claimed |
| US-7265144-B2 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-09-04 | — | — | US | claimed |
| EP-1567517-A1 | ANILINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | Bayer Pharmaceuticals Corporation (US) | 2005-08-31 | — | — | EP | claimed |
| US-20040157904-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION | 2004-08-12 | — | — | US | claimed |
| WO-2004050650-A1 | ANILINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-06-17 | — | — | WO | claimed |
| WO-2004050651-A1 | ANILINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-06-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | IAPP, GLP1R, GPR119 | ADORA1 749/4885ADORA3 111/4885ADORA2B 977/4885 |
| US-20040157904-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | IAPP, GLP1R, GPR119 | ADORA1 749/4885ADORA3 111/4885ADORA2B 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.